{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:05:48Z","timestamp":1790697948696,"version":"4.1.0"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Urothelial carcinoma (UC) is characterized by frequent recurrence, and accurate noninvasive tests remain needed for early detection and postoperative surveillance.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n \n To develop and validate a urine-based assay targeting\n AL021918.2<\/jats:italic>\n and vimentin (\n VIM<\/jats:italic>\n ) methylation for UC detection and postoperative surveillance.\n <\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This prospective, blinded, multicenter diagnostic study was performed at 3 tertiary medical centers in China. Samples were collected between December 1, 2021, and June 25, 2025. Consecutively enrolled adults with UC, benign urinary diseases, or nonurothelial malignant disease were included in a single-center training cohort, a 3-center validation cohort, and a prospective surveillance cohort. The surveillance cohort had a median follow-up of 6 months, completed December 13, 2023.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Urinary DNA methylation was assessed using quantitative methylation-specific polymerase chain reaction (PCR) analysis.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcomes were the sensitivity and specificity of the methylation assay for UC detection. Secondary outcomes included diagnostic performance according to tumor stage and grade and comparisons with urine cytology and fluorescence in situ hybridization (FISH).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This analysis included a total of 2307 participants, consisting of 643 in the training cohort (median age, 64 [IQR, 56-71] years; 494 men [76.8%]), 1620 in the validation cohort (median age, 67 [IQR, 61-73] years; 1129 men [69.7%]), and 44 with UC in the surveillance cohort (median age, 62 [IQR, 59-72] years; 32 men [72.7%]). The assay demonstrated sensitivities of 91.2% (95% CI, 87.6%-93.9%) in the training cohort and 90.8% (95% CI, 88.4%-92.8%) in the validation cohort and specificities of 90.0% (95% CI, 85.9%-93.2%) in the training cohort and 93.2% (95% CI, 91.3%-94.7%) in the validation cohort. In the training and validation cohorts, sensitivity remained high for Ta UC (79.6% [95% CI, 64.3%-89.7%] and 84.3% [95% CI, 77.8%-89.2%], respectively) and low-grade UC (86.4% [95% CI, 77.0%-92.5%] and 82.5% [95% CI, 75.7%-87.8%], respectively). Compared with urine cytology and FISH, the methylation assay demonstrated higher sensitivity while maintaining comparable specificity. After surgery, urinary methylation results were negative in 30 of 32 patients (93.8%) with positive preoperative results. During surveillance, the assay detected all 9 recurrences with a median lead time of 4.5 (IQR, 1.5-5.5) months before clinical confirmation and remained negative in 29 of 35 patients (82.9%) without recurrence.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this diagnostic study, a noninvasive PCR-based assay showed high diagnostic accuracy for UC detection and identified all observed recurrences during surveillance. The assay may serve as an adjunct for UC diagnosis and postoperative surveillance.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n Chinese Clinical Trial Registry Identifier:\n ChiCTR2300078302<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.36786","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:30:28Z","timestamp":1790695828000},"page":"e2636786","source":"Crossref","is-referenced-by-count":0,"title":["Urine Methylation Test for Urothelial Cancer Diagnosis and Surveillance"],"prefix":"10.1001","volume":"9","author":[{"given":"Yucai","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Urology, Peking University First Hospital, Beijing, China"},{"name":"Institute of Urology, Peking University, Beijing, China"},{"name":"National Urological Cancer Center, Beijing, China"},{"name":"Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencong","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital, Beijing, China"},{"name":"Institute of Urology, Peking University, Beijing, China"},{"name":"National Urological Cancer Center, Beijing, China"},{"name":"Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengwei","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital, Beijing, China"},{"name":"Institute of Urology, Peking University, Beijing, China"},{"name":"National Urological Cancer Center, Beijing, China"},{"name":"Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing, China"},{"name":"Department of Urology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"He","sequence":"additional","affiliation":[{"name":"Department of Urology, China-Japan Friendship Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiming","family":"He","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital, Beijing, China"},{"name":"Institute of Urology, Peking University, Beijing, China"},{"name":"National Urological Cancer Center, Beijing, China"},{"name":"Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanlan","family":"Dong","sequence":"additional","affiliation":[{"name":"Wuhan Ammunition Life-tech Company, Ltd, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Li","sequence":"additional","affiliation":[{"name":"Wuhan Ammunition Life-tech Company, Ltd, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital, Beijing, China"},{"name":"Institute of Urology, Peking University, Beijing, China"},{"name":"National Urological Cancer Center, Beijing, China"},{"name":"Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital, Beijing, China"},{"name":"Institute of Urology, Peking University, Beijing, China"},{"name":"National Urological Cancer Center, Beijing, China"},{"name":"Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninghan","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Urology, Wuxi No. 2 People\u2019s Hospital, Wuxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital, Beijing, China"},{"name":"Institute of Urology, Peking University, Beijing, China"},{"name":"National Urological Cancer Center, Beijing, China"},{"name":"Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital, Beijing, China"},{"name":"Institute of Urology, Peking University, Beijing, China"},{"name":"National Urological Cancer Center, Beijing, China"},{"name":"Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifeng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital, Beijing, China"},{"name":"Institute of Urology, Peking University, Beijing, China"},{"name":"National Urological Cancer Center, Beijing, China"},{"name":"Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Peking University First Hospital, Beijing, China"},{"name":"Institute of Urology, Peking University, Beijing, China"},{"name":"National Urological Cancer Center, Beijing, China"},{"name":"Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"issue":"3","key":"zoi260987r1","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up.","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"issue":"4","key":"zoi260987r2","doi-asserted-by":"publisher","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN Guidelines Insights: bladder cancer, version 3.2024.","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"zoi260987r3","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non\u2013muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel.","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"issue":"13","key":"zoi260987r4","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.3390\/cancers14133181","article-title":"Advances in diagnosis and therapy for bladder cancer.","volume":"14","author":"Hu","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"zoi260987r5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1200\/JCO.2014.57.6967","article-title":"Improving selection criteria for early cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients.","volume":"33","author":"Martin-Doyle","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi260987r6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2023 update.","volume":"84","author":"Roupr\u00eat","year":"2023","journal-title":"Eur Urol"},{"issue":"3","key":"zoi260987r7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"zoi260987r8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.eururo.2025.02.023","article-title":"European Association of Urology guidelines on upper urinary tract urothelial carcinoma: summary of the 2025 update.","volume":"87","author":"Masson-Lecomte","year":"2025","journal-title":"Eur Urol"},{"issue":"7679","key":"zoi260987r9","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1038\/551S48a","article-title":"Diagnostics: a flow of information.","volume":"551","author":"Wald","year":"2017","journal-title":"Nature"},{"issue":"7","key":"zoi260987r10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/cncy.21287","article-title":"uCyt+\/ImmunoCyt and cytology in the detection of urothelial carcinoma: an update on 7422 analyses.","volume":"121","author":"Comploj","year":"2013","journal-title":"Cancer Cytopathol"},{"issue":"12","key":"zoi260987r11","doi-asserted-by":"publisher","first-page":"922","DOI":"10.7326\/M15-0997","article-title":"Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis.","volume":"163","author":"Chou","year":"2015","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi260987r12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/npp.2012.112","article-title":"DNA methylation and its basic function.","volume":"38","author":"Moore","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"zoi260987r13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12032-022-01943-1","article-title":"DNA methylation and cancer: transcriptional regulation, prognostic, and therapeutic perspective.","volume":"40","author":"Bhootra","year":"2023","journal-title":"Med Oncol"},{"issue":"4","key":"zoi260987r14","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.euo.2018.06.011","article-title":"Performance of the bladder EpiCheck\u2122 methylation test for patients under surveillance for non\u2013muscle-invasive bladder cancer: results of a multicenter, prospective, blinded clinical trial.","volume":"1","author":"Witjes","year":"2018","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"zoi260987r15","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/JU.0000000000002748","article-title":"DNA methylation urine biomarkers test in the diagnosis of upper tract urothelial carcinoma: results from a single-center prospective clinical trial.","volume":"208","author":"Territo","year":"2022","journal-title":"J Urol"},{"issue":"2","key":"zoi260987r16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/CM9.0000000000002783","article-title":"An accurate diagnostic approach for urothelial carcinomas based on novel dual methylated DNA markers in small-volume urine.","volume":"137","author":"Wu","year":"2024","journal-title":"Chin Med J (Engl)"},{"issue":"20","key":"zoi260987r17","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"zoi260987r18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","article-title":"Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC).","volume":"35","author":"Soria","year":"2017","journal-title":"World J Urol"},{"issue":"19","key":"zoi260987r19","doi-asserted-by":"publisher","first-page":"4813","DOI":"10.3390\/cancers15194813","article-title":"Overview, diagnosis, and perioperative systemic therapy of upper tract urothelial carcinoma.","volume":"15","author":"Kolawa","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"zoi260987r20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13148-021-01029-1","article-title":"Clinical evaluation of Bladder CARE, a new epigenetic test for bladder cancer detection in urine samples.","volume":"13","author":"Piatti","year":"2021","journal-title":"Clin Epigenetics"},{"issue":"12","key":"zoi260987r21","doi-asserted-by":"publisher","first-page":"6278","DOI":"10.1172\/JCI139597","article-title":"Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer.","volume":"130","author":"Chen","year":"2020","journal-title":"J Clin Invest"},{"issue":"1","key":"zoi260987r22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s12916-023-03065-5","article-title":"A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients.","volume":"21","author":"Huang","year":"2023","journal-title":"BMC Med"},{"issue":"1","key":"zoi260987r23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12885-022-09268-y","article-title":"Improved urine DNA methylation panel for early bladder cancer detection.","volume":"22","author":"Fang","year":"2022","journal-title":"BMC Cancer"},{"issue":"11","key":"zoi260987r24","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.3390\/ijms20112657","article-title":"DNA-Methylation-based detection of urological cancer in urine: overview of biomarkers and considerations on biomarker design, source of DNA, and detection technologies.","volume":"20","author":"Larsen","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"5","key":"zoi260987r25","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.juro.2011.12.100","article-title":"Half of visible and half of recurrent visible hematuria cases have underlying pathology: prospective large cohort study with long-term followup.","volume":"187","author":"Mishriki","year":"2012","journal-title":"J Urol"},{"issue":"6","key":"zoi260987r26","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of urology guidelines on non\u2013muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014a summary of the 2024 guidelines update.","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"issue":"4","key":"zoi260987r27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non\u2013muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment.","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2854610\/wu_2026_oi_260987_1790096157.09119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:30:29Z","timestamp":1790695829000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2854610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.36786","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]}}}